Checkmab S.r.l. is a spin-off of the University of Milan (UniMi) and the National Institute of Molecular Genetics (INGM). The company researches and develops therapeutic monoclonal antibodies against tumor-infiltrating regulatory T lymphocytes (Tregs) for safer immunotherapy against different types of cancer.